Literature DB >> 22961478

Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose.

Xiao-Jing Sun1, Lei Zhao, Na Zhao, Xiao-Li Pan, Guo-Qiang Fei, Li-Rong Jin, Chun-Jiu Zhong.   

Abstract

OBJECTIVE: To determine whether high glucose enhances β-amyloid (Aβ) production in HEK293 Swedish mutant (APPsw) cells with Aβ precursor protein (APP) overexpression, and whether under this condition benfotiamine reduces the increased Aβ production.
METHODS: HEK293 APPsw cells were cultured with different concentrations of glucose for different times. The Aβ content in the supernatant was determined by ELISA. To investigate the mechanism by which benfotiamine reduced Aβ production, glycogen synthase kinase-3 (GSK-3) activity and expression were measured after the cells were cultured with 5.5 g/L glucose for 12 h.
RESULTS: With 1.0, 3.0, 4.5, 5.5, 6.5, 7.5, 8.5, or 10.5 g/L glucose, Aβ production by HEK293 APPsw cells was highest in the presence of 5.5 g/L glucose for 6 and 12 h. The difference in Aβ content between 5.5 and 1.0 g/L was most marked after incubation for 12 h. Benfotiamine at 20 and 40 μg/mL significantly reduced Aβ production in cells incubated with 5.5 g/L glucose for 12 h. Moreover, 40 μg/mL benfotiamine significantly enhanced the ratio of phosphorylated GSK-3 to total GSK-3, together with consistent down-regulation of GSK-3 activity.
CONCLUSION: High glucose increases Aβ production by HEK293 APPsw cells while benfotiamine prevents this increase. This is correlated with the modulation of GSK-3 activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961478      PMCID: PMC5561916          DOI: 10.1007/s12264-012-1264-0

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  30 in total

Review 1.  Diabetes mellitus and dementia.

Authors:  F Pasquier; A Boulogne; D Leys; P Fontaine
Journal:  Diabetes Metab       Date:  2006-11       Impact factor: 6.041

Review 2.  GSK-3 inhibitors for Alzheimer's disease.

Authors:  Jesús Avila; Félix Hernández
Journal:  Expert Rev Neurother       Date:  2007-11       Impact factor: 4.618

3.  Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis.

Authors:  S Gadau; C Emanueli; S Van Linthout; G Graiani; M Todaro; M Meloni; I Campesi; G Invernici; F Spillmann; K Ward; P Madeddu
Journal:  Diabetologia       Date:  2006-01-17       Impact factor: 10.122

4.  Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling.

Authors:  Valentina Marchetti; Rossella Menghini; Stefano Rizza; Alessia Vivanti; Tiziana Feccia; Davide Lauro; Akiyoshi Fukamizu; Renato Lauro; Massimo Federici
Journal:  Diabetes       Date:  2006-08       Impact factor: 9.461

Review 5.  Peripheral neuropathy: pathogenic mechanisms and alternative therapies.

Authors:  Kathleen A Head
Journal:  Altern Med Rev       Date:  2006-12

6.  ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways.

Authors:  Michelle L Steinhilb; R Scott Turner; James R Gaut
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

Review 7.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

9.  Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin.

Authors:  C G Jolivalt; C A Lee; K K Beiswenger; J L Smith; M Orlov; M A Torrance; E Masliah
Journal:  J Neurosci Res       Date:  2008-11-15       Impact factor: 4.164

10.  Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

Authors:  Ying Liu; Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-07-31       Impact factor: 5.372

View more
  5 in total

Review 1.  Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer's disease.

Authors:  Jian-Zhi Wang; Zhi-Hao Wang; Qing Tian
Journal:  Neurosci Bull       Date:  2014-03-14       Impact factor: 5.203

Review 2.  A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy.

Authors:  Kundlik Gadhave; Deepak Kumar; Vladimir N Uversky; Rajanish Giri
Journal:  Med Res Rev       Date:  2020-08-11       Impact factor: 12.388

3.  Benfotiamine attenuates inflammatory response in LPS stimulated BV-2 microglia.

Authors:  Iva Bozic; Danijela Savic; Danijela Laketa; Ivana Bjelobaba; Ivan Milenkovic; Sanja Pekovic; Nadezda Nedeljkovic; Irena Lavrnja
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

4.  Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.

Authors:  Lei Sheng; Wei Cao; Pingping Lin; Weili Chen; Hongrong Xu; Chunjiu Zhong; Fei Yuan; Hanjing Chen; Hui Li; Chao Liu; Mengjie Yang; Xuening Li
Journal:  Drug Des Devel Ther       Date:  2021-03-09       Impact factor: 4.162

Review 5.  Chronic over-nutrition and dysregulation of GSK3 in diseases.

Authors:  Xunxian Liu; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2016-08-04       Impact factor: 4.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.